(-0.37%) 5 264.50 points
(-0.85%) 38 196 points
(-0.25%) 18 756 points
(-0.32%) $78.98
(-0.19%) $2.66
(0.84%) $2 360.90
(-2.14%) $31.68
(-0.24%) $1 045.40
(-0.07%) $0.925
(-0.29%) $10.55
(-0.06%) $0.787
(0.21%) $89.76
@ $14.28
发出时间: 15 Feb 2024 @ 01:06
回报率: -37.18%
上一信号: Feb 14 - 03:46
上一信号:
回报率: -0.35 %
Live Chart Being Loaded With Signals
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States...
Stats | |
---|---|
今日成交量 | 831 515 |
平均成交量 | 996 857 |
市值 | 492.57M |
EPS | $0 ( 2024-05-09 ) |
下一个收益日期 | ( $-0.360 ) 2024-06-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.74 |
ATR14 | $0.0120 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-08 | Agarwal Sunil | Buy | 28 200 | Stock Option (Right to Buy) |
2024-04-05 | Agarwal Sunil | Buy | 0 | |
2024-04-01 | Morabito Christopher | Sell | 10 000 | Stock Option (Right to Buy) |
2024-04-01 | Morabito Christopher | Buy | 10 000 | Common Stock |
2024-04-01 | Morabito Christopher | Sell | 10 000 | Common Stock |
INSIDER POWER |
---|
96.99 |
Last 97 transactions |
Buy: 15 860 733 | Sell: 474 752 |
音量 相关性
Astria Therapeutics, Inc. 相关性 - 货币/商品
Astria Therapeutics, Inc. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-2.42 |
FY | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-2.42 |
FY | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-3.43 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-49.16 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。